X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Wockhardt with Panacea Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT LTD. vs PANACEA BIOTECH - Comparison Results

WOCKHARDT LTD.    Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT LTD. PANACEA BIOTECH WOCKHARDT LTD./
PANACEA BIOTECH
 
P/E (TTM) x -15.8 171.2 - View Chart
P/BV x 2.6 3.8 68.1% View Chart
Dividend Yield % 1.3 0.0 -  

Financials

 WOCKHARDT LTD.   PANACEA BIOTECH
EQUITY SHARE DATA
    WOCKHARDT LTD.
Mar-17
PANACEA BIOTECH
Mar-14
WOCKHARDT LTD./
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,129149 759.2%   
Low Rs62782 761.8%   
Sales per share (Unadj.) Rs363.184.1 431.6%  
Earnings per share (Unadj.) Rs-20.4-18.3 111.7%  
Cash flow per share (Unadj.) Rs-7.0-6.7 104.1%  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.10-  
Book value per share (Unadj.) Rs301.883.7 360.6%  
Shares outstanding (eoy) m110.5561.25 180.5%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x2.41.4 176.1%   
Avg P/E ratio x-42.9-6.3 680.6%  
P/CF ratio (eoy) x-125.9-17.2 730.1%  
Price / Book Value ratio x2.91.4 210.8%  
Dividend payout %-48.90-   
Avg Mkt Cap Rs m97,0637,074 1,372.0%   
No. of employees `0006.82.8 246.1%   
Total wages/salary Rs m9,6651,449 666.9%   
Avg. sales/employee Rs Th5,931.81,874.1 316.5%   
Avg. wages/employee Rs Th1,428.1527.0 271.0%   
Avg. net profit/employee Rs Th-334.0-407.7 81.9%   
INCOME DATA
Net Sales Rs m40,1465,154 779.0%  
Other income Rs m1,143100 1,144.8%   
Total revenues Rs m41,2895,254 785.9%   
Gross profit Rs m128-766 -16.7%  
Depreciation Rs m1,489711 209.5%   
Interest Rs m2,2531,503 149.9%   
Profit before tax Rs m-2,472-2,881 85.8%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-6 0.0%   
Extraordinary Inc (Exp) Rs m01,771 0.0%   
Tax Rs m-21117 -1,256.5%   
Profit after tax Rs m-2,260-1,121 201.6%  
Gross profit margin %0.3-14.9 -2.1%  
Effective tax rate %8.5-0.6 -1,464.5%   
Net profit margin %-5.6-21.8 25.9%  
BALANCE SHEET DATA
Current assets Rs m46,1603,810 1,211.5%   
Current liabilities Rs m19,2588,365 230.2%   
Net working cap to sales %67.0-88.4 -75.8%  
Current ratio x2.40.5 526.2%  
Inventory Days Days101156 64.7%  
Debtors Days Days9467 139.9%  
Net fixed assets Rs m40,16514,480 277.4%   
Share capital Rs m55361 901.6%   
"Free" reserves Rs m32,814903 3,633.5%   
Net worth Rs m33,3675,127 650.8%   
Long term debt Rs m31,9035,832 547.1%   
Total assets Rs m89,68719,433 461.5%  
Interest coverage x-0.1-0.9 10.6%   
Debt to equity ratio x1.01.1 84.1%  
Sales to assets ratio x0.40.3 168.8%   
Return on assets %02.0 -0.4%  
Return on equity %-6.8-21.9 31.0%  
Return on capital %-0.33.6 -9.2%  
Exports to sales %024.5 0.0%   
Imports to sales %010.2 0.0%   
Exports (fob) Rs mNA1,264 0.0%   
Imports (cif) Rs mNA525 0.0%   
Fx inflow Rs m9,1211,539 592.6%   
Fx outflow Rs m2,133942 226.5%   
Net fx Rs m6,988597 1,170.1%   
CASH FLOW
From Operations Rs m-2,695599 -449.7%  
From Investments Rs m-6,863-438 1,567.2%  
From Financial Activity Rs m12,545-303 -4,145.7%  
Net Cashflow Rs m3,010-141 -2,130.4%  

Share Holding

Indian Promoters % 74.5 74.5 100.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.3 0.6 383.3%  
FIIs % 7.7 1.3 592.3%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 23.6 65.3%  
Shareholders   67,757 10,259 660.5%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT LTD. With:   DISHMAN PHARMA  ELDER PHARMA  SUVEN LIFE  ALEMBIC PHARMA  CADILA HEALTHCARE  

Compare WOCKHARDT LTD. With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT LTD. SHARE PRICE


Feb 23, 2018 (Close)

TRACK WOCKHARDT LTD.

  • Track your investment in WOCKHARDT LTD. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON WOCKHARDT LTD.

WOCKHARDT LTD. 5-YR ANALYSIS

COMPARE WOCKHARDT LTD. WITH

MARKET STATS